2025-07-29 | Haemostatic disorders and lab findings - part 1 | 0:00 | 5 | |
|
2025-07-29 | Acute myocardial infarction morphological changes - part 4 | 0:00 | 0 | |
|
2025-07-29 | Von Willebrand disease - part 2 | 0:00 | 1 | |
|
2025-07-29 | Acute myocardial infarction morphological changes - part 3 | 0:00 | 1 | |
|
2025-07-29 | Von Willebrand disease - part 1 | 0:00 | 1 | |
|
2025-07-29 | Acute myocardial infarction morphological changes - part 2 | 0:00 | 0 | |
|
2025-07-29 | Factors affecting iron absorption | 0:00 | 1 | |
|
2025-07-29 | Acute myocardial infarction morphological changes - part 1 | 0:00 | 1 | |
|
2025-07-28 | Burkitts lymphoma - part 3 | 0:00 | 1 | |
|
2025-07-27 | Anemia - morphological classification part 2 | 0:00 | 0 | |
|
2025-07-27 | Modified dukes criteria infective endocarditis 2023 - part 3 | 0:00 | 0 | |
|
2025-07-27 | Anemia - morphological classification part 1 | 0:00 | 0 | |
|
2025-07-27 | Modified dukes criteria infective endocarditis 2023 - part 2 | 0:00 | 0 | |
|
2025-07-26 | Stains in pathology | 0:00 | 0 | |
|
2025-07-26 | Modified dukes criteria infective endocarditis 2023 - part 1 | 0:00 | 0 | |
|
2025-07-26 | Tumor markers - part 3 | 0:00 | 0 | |
|
2025-07-26 | Radiosensitive and radioresistant tumors | 0:00 | 0 | |
|
2025-07-26 | Tumor markers - part 2 | 0:00 | 0 | |
|
2025-07-26 | Vasculitis - modified chapel hill classification part 2 | 0:00 | 1 | |
|
2025-07-26 | Tumor markers - part 1 | 0:00 | 0 | |
|
2025-07-26 | Vasculitis - modified chapel hill classification part 1 | 0:00 | 1 | |
|
2025-07-25 | Macrophages and site | 0:00 | 0 | |
|
2025-07-25 | Vasculitis and their sites - part 2 | 0:00 | 0 | |
|
2025-07-25 | Immune cell and associated antigens | 0:00 | 0 | |
|
2025-07-25 | Histopathology named cells - part 2 | 0:00 | 0 | |
|
2025-07-25 | Vasculitis and their sites - part 1 | 0:00 | 0 | |
|
2025-07-25 | Systematic lupus erythematosus SLE - characteristic findings part 2 | 0:00 | 1 | |
|
2025-07-24 | Type 2 antibody mediated hypersensitivity - part 2 | 0:00 | 0 | |
|
2025-07-24 | Central nervous system tumours and their histopathological findings - part 5 | 0:00 | 0 | |
|
2025-07-24 | Type 2 antibody mediated hypersensitivity - part 3 | 0:00 | 0 | |
|
2025-07-24 | Histopathology named cells - part 1 | 0:00 | 0 | |
|
2025-07-24 | Systematic lupus erythematosus SLE - characteristic findings part 1 | 0:00 | 0 | |
|
2025-07-24 | Type 2 antibody mediated hypersensitivity - part 1 | 0:00 | 0 | |
|
2025-07-24 | Central nervous system tumours and their histopathological findings - part 4 | 0:00 | 0 | |
|
2025-07-24 | Non HLA genes associated with autoimmune diseases - part 2 | 0:00 | 2 | |
|
2025-07-24 | Central nervous system tumours and their histopathological findings - part 3 | 0:00 | 0 | |
|
2025-07-23 | Central nervous system tumours and their histopathological findings - part 2 | 0:00 | 0 | |
|
2025-07-23 | Transplant rejection reactions - part 4 | 0:00 | 0 | |
|
2025-07-23 | Central nervous system tumours and their histopathological findings - part 1 | 0:00 | 1 | |
|
2025-07-23 | Non HLA genes associated with autoimmune diseases - part 1 | 0:00 | 0 | |
|
2025-07-23 | Staining pattern and antigens - part 2 | 0:00 | 0 | |
|
2025-07-22 | Neurocutaneous syndromes - part 6 | 0:00 | 1 | |
|
2025-07-21 | Pathological named bodies - part 4 | 0:00 | 0 | |
|
2025-07-21 | Malignancies and translocations - part 2 | 0:00 | 0 | |
|
2025-07-21 | Pathological named bodies - part 3 | 0:00 | 0 | |
|
2025-07-21 | Malignancies and translocations - part 1 | 0:00 | 0 | |
|
2025-07-21 | Pathological named bodies - part 2 | 0:00 | 0 | |
|
2025-07-20 | Neurocutaneous syndromes - part 1 | 0:00 | 1 | |
|
2025-07-20 | Pathological named bodies - part 1 | 0:00 | 5 | |
|
2025-07-20 | Multiple myeloma and cells - part 2 | 0:00 | 2 | |
|
2025-07-20 | Vacutainers - part 2 | 0:00 | 0 | |
|
2025-07-20 | Multiple myeloma and cells - part 1 | 0:00 | 0 | |
|
2025-07-20 | Vacutainers - part 1 | 0:00 | 0 | |
|
2025-07-19 | Lymphomas and chromosomal translocations | 0:00 | 1 | |
|
2025-07-18 | Mallory bodies versus councilman bodies - part 2 | 0:00 | 0 | |
|
2025-07-17 | Hemolytic anaemia classification - part 3 | 0:00 | 0 | |
|
2025-07-17 | Mallory bodies versus councilman bodies - part 1 | 0:00 | 1 | |
|
2025-07-17 | Hemolytic anaemia classification - part 2 | 0:00 | 1 | |
|
2025-07-17 | Inheritance pattern of important diseases - part 5 | 0:00 | 1 | |
|
2025-07-17 | Inheritance pattern of important diseases - part 6 | 0:00 | 0 | |
|
2025-07-17 | Hemostatic disorders and lab findings - part 2 | 0:00 | 0 | |
|
2025-07-17 | Hemolytic anaemia classification - part 1 | 0:00 | 2 | |
|
2025-07-16 | Inheritance pattern of important diseases - part 4 | 0:00 | 1 | |
|
2025-07-15 | Von Willebrand disease - part 1 | 0:00 | 1 | |
|
2025-07-15 | Inheritance pattern of important diseases - part 1 | 0:00 | 0 | |
|
2025-07-15 | Factors affecting Iron absorption | 0:00 | 1 | |
|
2025-07-15 | Tumor suppressor gene - part 3 | 0:00 | 0 | |
|
2025-07-15 | Burkitts lymphoma - part 3 | 0:00 | 0 | |
|
2025-07-15 | Burkitts lymphoma - part 2 | 0:00 | 1 | |
|
2025-07-15 | Tumor suppressor gene - part 2 | 0:00 | 0 | |
|
2025-07-15 | Burkitts lymphoma - part 1 | 0:00 | 1 | |
|
2025-07-15 | Tumor suppressor gene - part 1 | 0:00 | 0 | |
|
2025-07-15 | Autoimmune hemolytic anaemia - part 3 | 0:00 | 0 | |
|
2025-07-15 | CK7 and CK20 markers in tumors | 0:00 | 0 | |
|
2025-07-14 | Autoimmune hemolytic anaemia - part 2 | 0:00 | 2 | |
|
2025-07-14 | Necrosis vs apoptosis - part 3 | 0:00 | 0 | |
|
2025-07-14 | Autoimmune hemolytic anaemia - part 1 | 0:00 | 1 | |
|
2025-07-14 | Necrosis vs apoptosis - part 2 | 0:00 | 0 | |
|
2025-07-14 | Anaemia - morphological classification part 2 | 0:00 | 0 | |
|
2025-07-14 | Onion eye appearance pathology - part 2 | 0:00 | 0 | |
|
2025-07-14 | Anemia - morphological classification part 1 | 0:00 | 0 | |
|
2025-07-14 | Necrosis vs apoptosis - part 1 | 0:00 | 0 | |
|
2025-07-13 | Stains in pathology | 0:00 | 2 | |
|
2025-07-13 | Onion eye appearance pathology - part 1 | 0:00 | 0 | |
|
2025-07-13 | Organisms and selective culture media - part 3 | 0:00 | 0 | |
|
2025-07-13 | Organisms and selective culture media - part 2 | 0:00 | 0 | |
|
2025-07-13 | Tumor markers - part 1 | 0:00 | 4 | |
|
2025-07-13 | Tumor markers - part 3 | 0:00 | 0 | |
|
2025-07-13 | Giant cell types | 0:00 | 1 | |
|
2025-07-13 | Granuloma and associated diseases - part 2 | 0:00 | 0 | |
|
2025-07-13 | Tumor markers - part 2 | 0:00 | 2 | |
|
2025-07-13 | Macrophages and site | 0:00 | 0 | |
|
2025-07-13 | Immune cells and associated antigens | 0:00 | 0 | |
|
2025-07-13 | Granuloma and associated diseases - part 1 | 0:00 | 0 | |
|
2025-07-12 | Histopathology named cells - part 2 | 0:00 | 1 | |
|
2025-07-12 | Vaginal infections - part 2 | 0:00 | 1 | |
|
2025-07-12 | Histopathology named cells - part 1 | 0:00 | 0 | |
|
2025-07-12 | Vaginal infections - part 1 | 0:00 | 0 | |
|
2025-07-12 | Non HLA genes associated with autoimmune diseases - part 2 | 0:00 | 0 | |
|
2025-07-12 | Type 2 antibody mediated hypersensitivity - part 2 | 0:00 | 1 | |
|